Literature DB >> 2645306

Leucine kinetics and the effects of hyperinsulinemia in patients with Cushing's syndrome.

P Tessari1, S Inchiostro, G Biolo, M C Marescotti, G Fantin, M T Boscarato, G Merola, F Mantero, A Tiengo.   

Abstract

As muscle wasting and resistance to insulin-mediated glucose utilization are features of Cushing's syndrome (CS), we examined glucose and amino acid metabolism in six patients with CS and six normal subjects before and during euglycemic hyperinsulinemic clamp studies (plasma insulin concentrations, approximately 0.36, approximately 0.65, and approximately 10.05 mmol/L). The two groups had similar body mass index values. In the postabsorptive state, leucine and alpha-ketoisocaproate (KIC) rates of appearance (Ra), KIC oxidation, and nonoxidized leucine-carbon flux, an index of leucine entering protein (Leu----P), were comparable in CS patients [2.38 +/- 0.14 (+/- SE), 0.22 +/- 0.04, and 2.16 +/- 0.12 mumol/kg.min) and in normal subjects (2.73 +/- 0.25, 0.17 +/- 0.02, and 2.59 +/- 0.22 mumol/kg.min). During the euglycemic clamp studies the leucine and KIC Ra values, KIC oxidation, and Leu----P decreased to a similar extent in both groups. In contrast, insulin-mediated glucose utilization was impaired in the CS patients at each clamp step (P less than 0.05). In summary, postabsorptive whole body leucine metabolism is normal in patients with CS and is normally suppressed by hyperinsulinemia, indicating a dissociation in insulin sensitivity with respect to glucose and amino acid metabolism.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2645306     DOI: 10.1210/jcem-68-2-256

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  1 in total

1.  Evaluation of circulating levels and renal clearance of natural amino acids in patients with Cushing's disease.

Authors:  A Faggiano; R Pivonello; D Melis; R Alfieri; M Filippella; G Spagnuolo; F Salvatore; G Lombardi; A Colao
Journal:  J Endocrinol Invest       Date:  2002-02       Impact factor: 4.256

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.